FDA 483 - Leading Edge Innovations, LLC - November 04, 2025

Leading Edge Innovations, LLC, a drug manufacturer in Branchburg, NJ, was inspected by the FDA and received a Form 483 with nine observations. The inspection revealed significant deficiencies across various aspects of drug manufacturing, including inadequate process validation, unqualified equipment, insufficient stability data, lack of raw material testing, poor cleaning validation and insanitary conditions, unsuitable facility construction, improper storage conditions, incomplete master production records, and a failure to conduct annual product reviews. These issues indicate a broad lack of adherence to cGMP requirements, posing potential risks to drug product quality, identity, strength, and purity.